ライフサイエンスコーパス: Kaplan-Meier curve

1 ll survival time and cancer recurrence using Kaplan-Meier curves.

2 dysfunction and failure) were compared using Kaplan-Meier curves.

3 Survival was analyzed with Kaplan-Meier curves.

4 elative CBV and time to progression by using Kaplan-Meier curves.

5 nd pouch retention rates were analyzed using Kaplan-Meier curves.

6 had and did not have PTNB was compared using Kaplan-Meier curves.

7 iers versus wild types was examined by using Kaplan-Meier curves.

8 was compared among white and Hispanics using Kaplan-Meier curves.

9 fully describes the actual survival based on Kaplan-Meier curves.

10 luation of which was by log rank analysis of Kaplan-Meier curves.

11 ome left ventricular ejection fraction using Kaplan-Meier curves.

12 Mortality over time was expressed with Kaplan-Meier curves.

13 ormed by descriptive methods and survival by Kaplan-Meier curves.

14 Survival was described using Kaplan-Meier curves.

15 hted Cox proportional hazards regression and Kaplan-Meier curves.

16 breast cancer diagnosis was plotted by using Kaplan-Meier curves.

17 d using C statistics, calibration plots, and Kaplan-Meier curves.

18 g-term allograft survival was compared using Kaplan-Meier curves.

19 Cumulative TB risk was estimated with Kaplan-Meier curves.

20 Survival was assessed using Kaplan-Meier curves.

21 imes to event outcomes were summarized using Kaplan-Meier curves.

22 nadjusted observed survival was inspected by Kaplan-Meier curves.

23 groups are compared using log-rank test and Kaplan-Meier curves.

24 and the prognostic value was determined with Kaplan-Meier curves.

25 Kaplan-Meier curve analysis indicated that the AS group

26 A Kaplan-Meier curve analysis revealed that the cumulative

27 lysis to determine adenovirus incidence, and Kaplan-Meier curve analysis to determine the timing of e

28 In Kaplan-Meier curve analysis, the median times to acquisi

29 and overall survival (OS) was assessed with Kaplan-Meier curves and a corresponding log-rank test fo

30 Survival analysis was conducted using Kaplan-Meier curves and a proportional hazards generaliz

31 Kaplan-Meier curves and adjusted Cox models were used to

32 Survival analysis employed Kaplan-Meier curves and adjusted Cox proportional hazard

33 We compared survival with Kaplan-Meier curves and analyzed the association between

34 We analysed cumulative rupture rates with Kaplan-Meier curves and assessed predictors with Cox pro

35 by stratified univariate log-rank test with Kaplan-Meier curves and by multivariate Cox proportional

36 ination and calibration were performed using Kaplan-Meier curves and calibration plots.

37 rtality for each tertile was determined with Kaplan-Meier curves and compared by the modified Peto-Pe

38 We created Kaplan-Meier curves and constructed multivariable Cox pr

39 urvival free from an AE was calculated using Kaplan-Meier curves and Cox hazard ratios were derived.

40 accine-targeted type; and 3) construction of Kaplan-Meier curves and Cox models to evaluate sequentia

41 Kaplan-Meier curves and Cox models were used to assess g

42 ospital all-cause mortality was evaluated by Kaplan-Meier curves and Cox proportional hazard modeling

43 ree from adverse events was calculated using Kaplan-Meier curves and Cox proportional hazard ratios w

44 Statistical analysis was performed using Kaplan-Meier curves and Cox proportional hazard ratios.

45 Kaplan-Meier curves and Cox proportional hazards models

46 Prognostic factors were evaluated using Kaplan-Meier curves and Cox proportional hazards models.

47 erapy/CCRT PET/CT imaging was examined using Kaplan-Meier curves and Cox proportional hazards models.

48 Statistical analysis was performed using Kaplan-Meier curves and Cox proportional hazards ratios.

49 lity of treatment weighting (IPTW) -adjusted Kaplan-Meier curves and Cox proportional hazards regress

50 ity and morbidity events were analyzed using Kaplan-Meier curves and Cox proportional hazards regress

51 Disease-free survival was examined using Kaplan-Meier curves and Cox proportional hazards regress

52 Survival analysis was performed using Kaplan-Meier curves and Cox proportional hazards regress

53 lity of treatment weighting (IPTW) -adjusted Kaplan-Meier curves and Cox regression analyses were use

54 Outcomes analysis was performed using Kaplan-Meier curves and Cox regression analysis.

55 Survival analysis included Kaplan-Meier curves and Cox regression models.

56 We used Kaplan-Meier curves and Cox regression to evaluate the a

57 site, was compared with regional data using Kaplan-Meier curves and Cox regression.

58 Survival analysis included Kaplan-Meier curves and Cox regressions.

59 Kaplan-Meier curves and generalised estimating equations

60 Kaplan-Meier curves and log-rank testing were used to co

61 OS and updated PFS data are presented using Kaplan-Meier curves and log-rank tests stratified for ho

62 Kaplan-Meier curves and log-rank tests were used to eval

63 Survival for CABG and PCI was compared using Kaplan-Meier curves and log-rank tests.

64 als for the three groups were compared using Kaplan-Meier curves and log-rank tests.

65 G and PCI survival rates were compared using Kaplan-Meier curves and log-rank tests.

66 Kaplan-Meier curves and proportional hazard ratios from

67 , Gleason scores, and stage were analyzed by Kaplan-Meier curves and the log-rank test.

68 iedman's test, and we analysed survival with Kaplan-Meier curves and the log-rank test.

69 Survival has been determined from Kaplan-Meier curves and treatment comparisons made with

70 Kaplan-Meier curves and univariable and multivariable Co

71 ver operating characteristic (ROC) analysis, Kaplan-Meier curves, and Cox proportional hazard regress

72 mes were assessed using frequency of events, Kaplan-Meier curves, and Cox proportional hazards regres

73 The log-rank test, Kaplan-Meier curves, and Cox regression compared surviva

74 Survival analysis was conducted using Kaplan-Meier curves, and Cox regression was used to iden

75 Discrimination using Kaplan-Meier curves, calibration curves, and bootstrap c

76 Kaplan-Meier curves compared time to event data between

77 Survival analysis showed that Kaplan-Meier curves comparing dosage interruption to ong

78 sing a Cox hazards model, the log-rank test, Kaplan-Meier curves, competing-risks regression, and con

79 Actuarial survival analysis using Kaplan-Meier curves, Cox regression and competitive risk

80 The Kaplan-Meier curves demonstrated improved arrhythmia-fre

81 9; logistic odds for events 0.44, p = 0.02); Kaplan-Meier curves demonstrated significant differences

82 Kaplan-Meier curves depict survival by nativity for Hisp

83 ox proportional hazards regression model and Kaplan-Meier curves determined whether black race affect

84 The Kaplan-Meier curves did not differ both for complete and

85 were seen in most diagnostic groups, but the Kaplan-Meier curves flattened out over time.

86 CCQ Overall Summary scores was assessed with Kaplan-Meier curves for death and all-cause hospitalizat

87 Kaplan-Meier curves for diagnosis of any cancer up to 10

88 During titration, the Kaplan-Meier curves for the combined end point of all-ca

89 The Kaplan-Meier curves for the probability of nonrecurrence

90 Kaplan-Meier curves for time to event for the primary ou

91 Kaplan-Meier curves for time to the secondary outcome of

92 al analysis demonstrates a divergence of the Kaplan-Meier curves in favor of patients in whom APBF wa

93 e extracted from the text of articles or the Kaplan-Meier curves independently by investigators who w

94 nder the curve of 0.85 vs. 0.74 for BNP) and Kaplan-Meier curves (log rank: 17.5 vs. 9.95).

95 Kaplan-Meier curves (log-rank analyses) were used to est

96 immunohistochemistry were investigated using Kaplan-Meier curves, log rank tests, and Cox regression

97 Kaplan-Meier curves, log-rank analysis, and Cox proporti

98 sion-free survival (PFS) were compared using Kaplan-Meier curves, log-rank tests and Cox models.

99 database performed between 1991 and 2003 by Kaplan-Meier curves, log-rank tests, and Cox proportiona

100 Survival analysis was performed with the Kaplan-Meier curve method (log rank test; P < 0.05).

101 redictors of survival were analyzed with the Kaplan-Meier curve method (log-rank test) and multivaria

102 Kaplan-Meier curves of EAC incidence were stratified by

103 r uniformity at a coarse scale value of 2.5, Kaplan-Meier curves of the proportion of patients withou

104 rence in 3-month survival was observed using Kaplan-Meier curves (P =.11).

105 Kaplan-Meier curve reconstruction did not show significa

106 The Kaplan-Meier curve showed that CCI-779 significantly inc

107 Kaplan-Meier curves showed 1-year survival after first s

108 Kaplan-Meier curves showed fewer patients with AA athero

109 Kaplan-Meier curves showed global allograft survival dif

110 Kaplan-Meier curves showed longer median disease-specifi

111 The Kaplan-Meier curves showed significant differences in fa

112 The adjusted Kaplan-Meier curves showed significantly lower survival

113 Kaplan-Meier curves showed that both high and low PIP4K2

114 Adjusted Kaplan-Meier curves showed that individuals with a FRS =

115 IPTW-adjusted Kaplan-Meier curves showed that median OS was significan

116 IPTW-adjusted Kaplan-Meier curves showed that median OS was significan

117 Kaplan-Meier curves showed that reduced Ks and prolonged

118 Kaplan-Meier curve shows 86.5% and 94.6% (P=0.086) and p

119 The Kaplan-Meier curve shows a 4-year probability of develop

120 The Kaplan-Meier curve significantly favored TEVAR for the e

121 t important finding of the study was that in Kaplan-Meier curves stratified by mean dose, longer PFS

122 Kaplan-Meier curves stratified by sex and proviral load

123 Survival rates computed from stage-specific Kaplan-Meier curves (time to melanoma-specific death) we

124 We used Kaplan-Meier curves to compare patient survival between

125 eveloped Cox proportional hazards models and Kaplan-Meier curves to compare women who underwent oopho

126 f IGF-1 and VEGF with overall survival (OS), Kaplan-Meier curves to estimate OS, and recursive partit

127 We used Kaplan-Meier curves to estimate the cumulative probabili

128 We used Kaplan-Meier curves to show graft survival.

129 With regard to overall mortality (Kaplan-Meier curves), univariate analysis also revealed

130 Kaplan-Meier curve was significantly different between g

131 Kaplan-Meier curve was used to estimate patients' probab

132 bility of VT/VF: two-year risk of VT/VF from Kaplan-Meier curves was 40% in highest quartile versus 2

133 Valve survival analysis (Cox regression and Kaplan-Meier curves) was used to study the natural progr

134 Kaplan-Meier curves were compared by using log-rank test

135 Kaplan-Meier curves were constructed for the time to fir

136 Kaplan-Meier curves were constructed to compare survival

137 Kaplan-Meier curves were constructed to determine late r

138 Kaplan-Meier curves were constructed to evaluate limb sa

139 Kaplan-Meier curves were created for presence of ER and

140 For each of these primary endpoints, Kaplan-Meier curves were generated and log-rank tests we

141 Kaplan-Meier curves were generated by cohort for time un

142 Kaplan-Meier curves were generated to assess differences

143 Kaplan-Meier curves were plotted to determine the incide

144 Predictive Kaplan-Meier curves were used to compare the linear pred

145 Kaplan-Meier curves were used to compare the unadjusted

146 grouped using propensity score methods, and Kaplan-Meier curves were used to compare time to measles

147 Kaplan-Meier curves were used to depict persistence over

148 Kaplan-Meier curves were used to estimate distant-diseas

149 Kaplan-Meier curves were used to estimate survival.

150 Kaplan-Meier curves were used to evaluate prognostic val

151 Kaplan-Meier curves were used to explore the association